Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 9/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14590569 | 0.88 | OPRM1 (0.45) | OPRM1OPRD1TP53MAOB | |
| SCHEMBL13651823 | 0.85 | MAPT (0.39) | MAOBHRH3 | |
| SCHEMBL14590557 | 0.85 | NPC1 (0.38) | — | |
| SCHEMBL13183274 | 0.84 | NQO1 (0.47) | MAOB | |
| SCHEMBL4806456 | 0.81 | NPC1 (0.48) | MAOBHRH3 | |
| SCHEMBL13651779 | 0.81 | ALDH1A1 (0.49) | MAOB | |
| SCHEMBL13651821 | 0.81 | ALDH1A1 (0.36) | APP | |
| SCHEMBL10329392 | 0.80 | ALDH1A1 (0.53) | TP53APPHRH3 | |
| SCHEMBL4810156 | 0.80 | MAPT (0.38) | — | |
| SCHEMBL4809265 | 0.80 | MAPT (0.35) | MAOBHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222436-B2 | Oxetane compound, active energy ray-curable composition, active energy ray-curable ink composition and inkjet recording method | FUJIFILM CORPORATION (JP) | 2012-07-17 | — | — | US | disclosed |
| US-8222436-B2 | Oxetane compound, active energy ray-curable composition, active energy ray-curable ink composition and inkjet recording method | FUJIFILM CORPORATION (JP) | 2012-07-17 | — | — | US | disclosed |
| US-20110052831-A1 | NOVEL OXETANE COMPOUND, ACTIVE ENERGY RAY-CURABLE COMPOSITION, ACTIVE ENERGY RAY-CURABLE INK COMPOSITION AND INKJET RECORDING METHOD | FUJIFILM CORPORATION (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20110052831-A1 | NOVEL OXETANE COMPOUND, ACTIVE ENERGY RAY-CURABLE COMPOSITION, ACTIVE ENERGY RAY-CURABLE INK COMPOSITION AND INKJET RECORDING METHOD | FUJIFILM CORPORATION (JP) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110052831-A1 | NOVEL OXETANE COMPOUND, ACTIVE ENERGY RAY-CURABLE COMPOSITION, ACTIVE ENERGY RAY-CURABLE INK COMPOSITION AND INKJET RECORDING METHOD | OXER1, NOX1, NOX4 | OPRM1 861/4885OPRD1 719/4885TP53 4126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.